Current view on the etiology and neurochemistry of anxiety-depressive disorders. Part 1
https://doi.org/2618-6667-2018-71-109-122
Abstract
The 1 part deals with the review of current foreign and domestic views on the etiology, neurochemistry, and pathophysiology of anxiety-depressive disorders. Theories of emergence, neuromediator systems, and anatomic structures, engaged in the pathogenesis of anxiety-depressive disorders, were discussed. On this basis current trends of pathogenetic therapy of anxiety will be presented in the second part.
About the Authors
Olessya Tereshchenko
FSBSI «Mental Health Research Centre», Moscow
Russian Federation
MD, junior researcher, laboratory of pathophysiology
Russian Federation
MD, junior researcher, laboratory of pathophysiology
Natalia Kost
FSBSI «Mental Health Research Centre», Moscow
Russian Federation
PhD, doctor of biological sciences, professor, chief researcher, laboratory of pathophysiology
Russian Federation
PhD, doctor of biological sciences, professor, chief researcher, laboratory of pathophysiology
References
1. Krasnov V.N. Trevozhnye rasstrojstva: ih mesto v sovremennoj sistematike i podhody k terapii. Social’naya i klinicheskaya psihiatriya. 2008;18(3):33–38. (In Russ.).
2. Andruh P.G. Ehtiologiya, nejrohimiya i klinika sovremennyh form trevozhno-depressivnyh rasstrojstv. Medicinskie issledovaniya. 2001;1(1):109–110. (In Russ.).
3. Gorman J. M. Anxiety disorders: Introduction and overview. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry 17th ed. on CD- ROM. Lippincott: Williams & Wilkins, 2000.
4. Klein D.F. Historical aspects of anxiety. Dialogues Clin. Neurosci. 2002;4:295–304.
5. Lambert M.V., Senior C., Fewtrell W.D., Phillips M.L., David A.S. Primary and secondary depersonalisation disorder: a psychometric study. J. Affect. Dis. 2001;63(1–3):249–256.
6. Snezhnevskij A.V. Rukovodstvo po psihiatrii. M.: Medicina, 1983. T. 1. (In Russ.).
7. Barlow D.H. Anxiety and its disorders: the nature and treatment of anxiety and panic. 2nd ed. New York: Guilford Press, 2001.
8. Chisholm D., Sweeny K., Sheehan P., Rasmussen B., Smit F., Cujpers P., Saxena S. Scaling-up treatment of depression and anxiety: a global return on investment analisis. The Lancet Psychiatry. 2016;3(5):415–424.
9. Programma VOZ po zapolneniyu probelov v oblasti ohrany psihicheskogo zdorov’ya. URL: http://www.who.int/ru/ [sajt VOZ] (In Russ.)
10. Bijl R. V., Ravelli A., van Zessen G. Prevalence of psychiatric disorder in the general population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc. Psychiatry Psychiatr. Epidemiol. 1998;33(12):587–595.
11. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Ehleman S., Wittchen H.U., Kendler K.S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry. 1994;51(1):8–19.
12. Sartorius N., Ustün T.B., Lecrubier Y., Wittchen H.U. Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. British journal of psychiatry. 1996;168(30):38–43.
13. Blazer D.G., Hughes D., George L.K., Swartz M., Boyer R. Generalized anxiety disorder. Psychiatric disorders in America: The Epidemiolgic Catchment Area study / Eds. L.N. Robins, D.A. Regier. New York: Free Press, 1991:180–203.
14. Faravelli C., Guerrini Degl’Innocenti B., Giardinelli L. Epidemiology of anxiety disorders in Florence. Acta Psychiatr. Scand. 1989;79(4):308–312.
15. Hwu H.G., Yeh E.K., Chang L.Y. Prevalence of psychiatric disorders in Taiwan defined by the Chinese Diagnostic Interview Schedule. Acta Psychiatr. Scand. 1989;79(2):136–147.
16. Lee C.K., Kwak Y.S., Yamamoto J., Rhee H., Kim Y.S., Han J.H., Choi J.O., Lee Y.H. Psychiatric epidemiology in Korea. Part I: Gender and age differences in Seoul. J. Nerv. Ment. Dis. 1990;178(4):242–246.
17. Uhlenhuth E.H., Balter M.B., Mellinger G.D. Symptom checklist syndromes in the general population. Correlations with psychotherapeutic drug use. Arch. Gen. Psychiatry. 1983;40(11):1167–1173.
18. Spitzer R.L., Kroenke K., Linzer M., Hahn S.R., Williams J.B., deGruy F.V et al. Health-related quality of life in primary care patients with mental disorders: Results from the PRIME MD 1000 Study. Journal of American Medical Association. 1995;274(19):1511–1517.
19. Roy-Byrne P.P., Katon W. Generalized anxiety disorder in primary care: the precursor/modifier pathway to increased health care utilization. Journal of Clinical Psychiatry. 1997;58(3):34–38.
20. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry. 2005;Jun;62(6):617–627. doi: 10.1001/archpsyc.62.6.617
21. Wittchen H.U., Carter R.M., Pfister H. et al. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int. Clin. Psychopharmacol. 2000;15(6):319–328.
22. Avedisova A.S. Kontrolirovanie simptomov trevogi i lechenie trevozhno-fobicheskih rasstrojstv — al’ternativa ili net? Psihiatriya i psihofarmakoterapiya im. P.B. Gannushkina. 2006;8(5):23–28. (In Russ.).
23. Vertogradova O.P. Trevozhno-fobicheskie rasstrojstva i depressiya. Trevoga i obsessii / Pod red. A.B. Smulevicha. M.: NCPZ RAMN, 1998: 113–131. (In Russ.).
24. Maj M., Akiskal H.S., Lopez-Ibor J.J., Okasha A. (Eds.). Phobias. Chichester: John Wiley & Sons, 2004.
25. Nutt D.J., Rickels K., Stein D.J. Generalized anxiety disorders: symptomatology, pathogenesis and management. London: Martin Dunitz, 2002.
26. Starcevic V. Anxiety disorders in adults. A clinical guide. Oxford etc: Oxford University Press, 2005.
27. Stein D.J., Hollander E., Rothbaum B.O. Textbook of anxiety disorders. Washington etc: American Psychiatric Publishing, 2002.
28. Lapin I.P. Stress. Trevoga. Depressiya. Alkogolizm. Ehpilepsiya. SPb.: DEAN, 2004. (In Russ.).
29. Gorman J.M., Sloan R.P. Heart rate variability in depressive and anxiety disorders. Am. Heart J. 2000;Oct;140(4):77–83.
30. Gorwood P. Generalized anxiety disorder and major depressive disorder comorbidity: An example of genetic pleiotropy? European Psychiatry. 2004;19(1):27–33. doi: 10.1016/j.eurpsy.2003.10.002
31. Kendler K.S. Major depression and generalized anxiety disorder. Same genes (partly) different environments — revisited. Br. J. Psychiatry. 1996;June;30:68–75.
32. Lewis A. The state of psychiatry: essay and addresses. New York: Science House, 1967:179–194.
33. Schlegel S., Steinert H., Bocksich A. et al. Decreased benzodiazepine receptor binding in panic disorder measured by lomazenil-SPECT. A preliminary report. Eur. Arch. Psychiatry Clin. Neurosci. 1994;244(1):49–51.
34. Weissman M.M., Klerman G.L., Markowitz J.S., Ouellette R. Suicidal ideation and suicide attempts in panic disorder and attacks. New England Journal of Medicine. 1989;321(18):1209–1214.
35. Krasnov V.N. Nauchno-prakticheskaya programma «Vyyavlenie i lechenie depressij v pervichnoj medicinskoj seti». Social’naya i klinicheskaya psihiatriya. 1999;9(4):5–9. (In Russ.).
36. Krasnov V.N., Bobrov A.E., Dovzhenko T.I., Vel’tishchev D.Yu., Shishkov S.N., Antipova O.S., Yal’ceva N.V., Bannikov G.S., Holmogorova A.B., Garanyan N.G. Sovershenstvovanie metodov rannej diagnostiki psihicheskih rasstrojstv (na osnove vzaimodejstviya so specialistami pervichnogo zvena zdravoohraneniya) / Pod red. V.N. Krasnova. M.: Medpraktika-M, 2008. (In Russ.).
37. Hirschfeld R.M. A. placebo response in the treatment of panic disorder. Bulletin of the Menninger Clinic. 1996;60(2):А76–А86.
38. Keller M.B., Baker L.А. The clinical course of panic disorder and depression. Journal of Clinical Psychiatry. 1992;53:5–8.
39. Marks I., Lader M. Anxiety states (anxiety neurosis): A review. Journal of Nervous and Mental Disease. 1973;156(1):3–18.
40. Noyes R. Jr., Clancy J., Hoenk P.R., Slymen D.J. The prognosis of anxiety neurosis. Archives of General Psychiatry. 1980;37(2):173–178.
41. British National Formulary № 31. British Medical association and Royal pharmaceutical society of Great Britain. London, 1996.
42. Wittchen H.U., Kessler R.C., Pfister H., Lieb R. Why do people with anxiety disorders become depressed? A prospective longitudinal community study. Acta Psychiatr. Scand. 2000;102(406):14–23.
43. Blalock J.E. The syntax of immune-neuroendocrine communication. Immunol. Today. 1994;15:504–511.
44. Kessler R.C., Du Pont R.L., Berglund P., Wittchen H.U. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am. J. Psychiatry. 1999;156(12):1915–1923.
45. Kessler R.C., Keller M.B., Wittchen H.U. The epidemiology of generalized anxiety disorder. Psychiatr. Clin. North Am. 2001;24(1):19–39.
46. Coryell W., Noyes R., House J.D. Mortality among outpatients with anxiety disorders. American Journal of Psychiatry. 1986;143(4):508– 510.
47. Katsura M., Ohkuma S. Functional involvement of endogenous anxiogenic neuropeptide in brains. Nihon Shinkei Seishin Yakurigaku Zasshi. 2004;Jun;24(3):119–123.
48. Gaynes B.N., Rush A.J., Trivedi M.H., Wisniewski S.R., Balasubramani G.K., Spencer D.C., Petersen T., Klinkman M., Warden D., Nicholas L., Fava M. Major depression symptoms in primary care and psychiatric care settings: A cross-sectional analysis. Ann. Family Medicine. 2007;5:126–134. doi: 10.1370/afm.641
49. Hofmann S.G., Barlow D.H. The costs of anxiety disorders: Implications for psychosocial interventions. Cost-effectiveness of psychotherapy: A guide for practitioners, researchers, and policymakers / Ed. N.E. Miller, K.M. Magruder. New York: Oxford University Press, 1999:224–234.
50. Vsemirnaya organizaciya zdravoohraneniya. Doklad o sostoyanii zdravoohraneniya v mire — 2001. Psihicheskoe zdorov’e: Novoe ponimanie, novaya nadezhda. Zheneva: VOZ 2001;215. (In Russ.).
51. Danilova H.H., Krylova A.L. Fiziologiia vysshei nervnoi deiatel’nosti. Rostov n/D: Feniks, 2005.
52. Schulkin J. Neuroendocrine regulation of behavior. Cambridge, UK: Cambridge University Press, 1999.
53. Shekhar A., McCann U.D., Meaney M.J., Blanchard D.C., Davis M., Frey K.A., Liberzon I., Overall K.L., Shear M.K., Tecott L.H., Winsky L. Summary of a National Institute of Mental Health workshop: developing animal models of anxiety disorders. Psychopharmacology (Berl.). 2001;Oct;157(4):327–339. doi: 10.1007/s002130100859
54. Shekhar A., Sajdyk T.S., Keim S.R., Yoder K.K., Sanders S.K. A role of the basolateral amygdala in panic disorder. Ann. N.-Y. Acad. Sci. 1999;Jun 29;877:747–750.
55. Song C., Leonard B.E. The olfactory bulbectomised rat as a model of depression. Neurosci. Biobehav. Rev. 2005;29(4–5):627–647. doi: 10.1016/j.neubiorev.2005.03.010
56. Barad M. Fear extinction in rodents: basic insight to clinical promise. Curr. Opin. Neurobiol. 2005;Dec;15(6):710–715. doi: 10.1016/ j.conb.2005.10.005
57. Chrousos G.P., Gold P.W. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA. 1992;Mar 4;267(9):1244–1252.
58. Otellin V.A., Arushanyan E. Nigrostrionigral’naya sistema M., 1989. (In Russ.).
59. Vythilingam M., Anderson E.R., Goddard A., Woods S.W., Staib L.H., Charney D.S., Bremner J.D. Temporal lobe volume in panic disorder — a quantitative magnetic resonance imaging study. Psychiatry Res. 2000;Aug28;99(2):75–82.
60. Amaro K., Tanikawa T., Iseki H., Notami M., Kawamura H., Kitamura K. Single neuron analysis of the human midbrain tegmentum. Rostral mecencephalic reticulotomy for pain relief. Appl. Neurophysiol. 1978;41:66–78.
61. Bonne O., Grillon C., Vythilingam M., Neumeister A., Charney D.S. Adaptative and maladaptative psychobiological responses to severe psychological stress: implications for the discovery of novel pharmacotherapy. Neuroscience and Biobehavioral Reviews. 2004; Mar;28(1):65–94. doi: 10.1016/j.neubiorev.2003.12.001
62. Storozhakova Ya.A. Psihovegetativnye krizy i ih svyaz’ s prolapsom mitral’nogo klapana (obzor literatury). «Soyuzmedinform», Ehkspress-informaciya, seriya «Terapiya». M., 1990. Vyp. 2. (In Russ.).
63. Laakmann G. Psychopharmacoendocrinology and depression research. Berlin: Springer, 1991.
64. Meltzer H.Y., Lowy M. T. The serotonin hypothesis of depression. Psychopharmacology: The third generation of progress. N.Y.: Raven Press, 1987:513–526.
65. Randrup A., Braestrup C. Uptake inhibition of biogenic amines by newer antidepressant drugs: relevance to the dopamine hypothesis of depression. Psychopharmacology. 1977;53(3):309–314.
66. Praag H.M. Monoamines and depression. Pharmacopsychiatria. 1969;2:151–160.
67. Hales R.E., Yudofsky S.C., Talbott J.A. Textbook of Psychiatry. 3rd ed. Washington: American Psychiatric Press, 1999.
68. Cloninger C.R., Zohar A.H., Hirschmann S., Dahan D. The psychological costs and benefits of being highly persistent: personality profiles distinguish mood disorders from anxiety disorders. J. Affect. Disord. 2012;Feb;136(3):758–766. doi: 10.1016/j.jad.2011.09.046.
69. Akiyoshi J. Neuropharmacological and genetic study of panic disorder. Nihon Shinkei Seishin Yakurigaku Zasshi. 1999;Jul;19(3):93–99.
70. Albert P.R., Fiori L.M. Transcriptional dys-regulation in anxiety and major depression: 5-HT1A gene promoter architecture as a therapeutic opportunity. Curr. Pharm. Des. 2014;20(23):3738–3750.
71. Holmes A. Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease. Neurosci. Biobehav. Rev. 2008; Sep;32(7):1293–1314. doi: 10.1016/j.neubiorev.2008.03.006
72. Aouizerate B., Martin-Guehl C., Tignol J. Neurobiology and pharma-cotherapy of social phobia. Encephale. 2004;Jul-Aug;30(4):301–313.
73. Avedisova A. S., Zaharova, K. V., Marachev M. P. Effektivnost’ val’doksana (agomelatina) pri lechenii pacientov s trevozhnoj depressiej v ramkah bol’shogo depressivnogo rasstrojstva: rezul’taty observacionnoj programmy «Dzhaz». Psihiatriya i psihofarm. 2009;6:15–19. (In Russ.).
74. Goto K. Melatonin. Nihon Rinsho. 2005;Aug;63(8):585–587.
75. Brewerton T.D., Lydiard R.B., Johnson M., Ballenger J.C., Fossey M.D., Zealberg J.J., Roberts J.E. CSF serotonin: diagnostic and seasonal differences. Biol. Psychiatry. 1995;37(9):655–655.
76. Ashmarin I.P. Biohimiya mozga: Uch. posobie / Pod red. I.P. Ashmarina, P.V. Stukalova, N.D. Eshchenko. SPb.: Izd-vo SPb. un-ta, 1999. (In Russ.).
77. Van Bockkstaele E.G., Bajic D., Proudfit H., Valentino R. J. Topographic architecture of stress-related pathways targeting the noradrenergic locus coeruleus. Physiol. Behav. 2001;Jun;73(3):273–283.
78. Mitchelson F.J. The pharmacology of McN-A-343. Pharmacol. Ther. 2012;Aug;135(2):216–245. doi: 10.1016/j.pharmthera.2012.05.008
79. Wall P.M., Flinn J., Messier C. Infralimbic muscarinic M1 receptors modulate anxiety-like behaviour and spontaneous working memory in mice. Psychopharmacology (Berl.). 2001;Apr;155(1):58–68.
80. Picciotto M. R., Mineur Y. S. Molecules and circuits involved in nicotine addiction: The many faces of smoking. Neuropharmacology. 2014;Jan;76 Pt B:545–553. doi: 10.1016/j.neuropharm.2013.04.028
81. Salgado-Pineda Р., Delaveau P., Blin O., Nieoullon A. Dopaminergic contribution to the regulation of emotional perception. Clin. Neuropharmacol. 2005;Sep-Oct;28(5):228–237.
82. Beaulieu J.M., Gainetdinov R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 2011; Mar;63(1):182–217. doi: 10.1124/pr.110.002642
83. Alex K.D., Yavanian G.J., McFarlane H.G. Modulation of dopamine release by striatal 5-HT2C receptors. Synapse. 2005;Mar15;55(4): 242–251. doi: 10.1002/syn.20109
84. Argyropoulos S.V., Bell C.J., Nutt D.J. Brain function in social anxiety disorder. Psychiatr. Clin. North Am. 2001;Dec;24(4):707–722.
85. Yahno N.N., Preobrazhenskaya I.S. Pronoran v lechеnii bol’nyh s rannimi stadiyami bolezni Parkinsona. Nevrologicheskij zhurnal. 2004;9(6):34–38. (In Russ.).
86. Sem’yanov, A.V. GAMK-ehrgicheskoe tormozhenie v CNS: tipy GAMK-receptorov i mekhanizmy tonicheskogo GAMK-oposredovannogo tormoznogo dejstviya. Nejrofiziologiya/Neurophysiology. 2002;34(1):82-92. (In Russ.).
87. Smulevich A.B., Drobizhev M.Yu., Ivanov S.V. Trankvilizatory – proizvodnye benzodiazepina v psihiatrii i obshchej medicine. M.: Media Sfera, 1999. (In Russ.).
88. Schlegel S., Steinert H., Bocksich A., Hahn K., Schloesser R., Benkert O. Decreased benzodiazepine receptor binding in panic disorder measured by lomazenil-SPECT. A preliminary report. Eur. Arch. Psychiatry Clin. Neurosci. 1994;244(1):49–51.
89. Medvedev V.E., Frolova V.I., Epifanov A.V. Novye vozmozhnosti farmakoterapii psihicheskih rasstrojstv u pacientov s serdechno-sosudistymi zabolevaniyami. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2014;9:30–37. (In Russ.).
90. Smulevich A.B., Volel’ B.A., Ternovaya E.S., Nikitina Yu.M. Primenenie preparata pantogam aktiv (D-, L-gopantenovaya kislota) v terapii kognitivnyh i trevozhnyh rasstrojstv u pacientov s arterial’noj gipertenziej. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2015;12:40–49. (In Russ.). doi: 10.17116/jnevro201511511240-49
91. Chojnacka-Wójcik E., Kłodzinska A., Pilc A. Glutamate receptor li- gands as anxiolytics. Curr. Opin. Investig. Drugs. 2001:Aug;2(8):1112– 1119.
Review
For citations:
Tereshchenko O., Kost N. Current view on the etiology and neurochemistry of anxiety-depressive disorders. Part 1. Psychiatry (Moscow) (Psikhiatriya). 2018;1(77):109-122. (In Russ.) https://doi.org/2618-6667-2018-71-109-122
Views:
1317
Email this article 
